Patents by Inventor Anders Wieslander

Anders Wieslander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10369266
    Abstract: The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ?10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: August 6, 2019
    Assignee: GAMBRO LUNDIA AB
    Inventors: Petra Åhl, Gabriela Godaly, Jan Sternby, Anders Wieslander
  • Publication number: 20190151265
    Abstract: The invention provides a first concentrate comprising lactate and calcium ions, said first concentrate having increased stability against precipitation at temperatures around +4° C., said first concentrate being useful for preparing a ready-to-use dialysis fluid by mixing said first concentrate with water and optionally a second concentrate comprising glucose, wherein that the lactate concentration Lconc (expressed in moles per litre, M) of the concentrate fulfills the conditions: a) Lconc>0.8 M; and b) Lconc<(1.9?0.4×Caready) M; and wherein Caready is the calcium concentration of the ready-to-use dialysis fluid expressed in millimoles per litre (mM).
    Type: Application
    Filed: May 5, 2017
    Publication date: May 23, 2019
    Inventors: Anders Wieslander, Ola Carlsson, Karin Sandin, Simon Enarsson, Viktoria Hancock
  • Publication number: 20190151526
    Abstract: The present invention concerns a system for preparing a ready-to-use peritoneal dialysis fluid. The system comprises a) a proportioning device; b) at least one source of water; c) at least one source of first concentrate adapted for connection with a) and b), d) at least one source of second concentrate adapted for connection with a) and b), and optionally, e) at least one source of further concentrate adapted for connection with a) and b), wherein the first concentrate comprises glucose and has a pH of between 1.5 and 4, and wherein the second concentrate comprises a physiologically acceptable buffer and has a pH of between 5.5 and 9.0.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 23, 2019
    Inventors: Anders Wieslander, Olof Jansson, Ola Carlsson, Sture Hobro, Karin Sandin, Simon Enarsson
  • Publication number: 20190125954
    Abstract: A renal failure therapy system includes: (i) a dialysis fluid pumping unit including a dialysis fluid pump; (ii) a disposable set operable with the dialysis fluid pumping unit such that the dialysis fluid pump can pump dialysis fluid from the disposable set; (iii) a concentrate in fluid communication with the disposable set, wherein the concentrate is used to prepare the dialysis fluid; and (iv) a control unit operating the dialysis fluid pump, the control unit configured to cause a portion of the concentrate to fill at least a portion of the disposable set between treatments, the concentrate operating as a disinfectant allowing the disposable set to be used for multiple treatments with the same dialysis pumping unit.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 2, 2019
    Inventors: Sarah Lynn Mathiot, Anders J. Wellings, Jeffrey Cook, Edward Szpara, Anders Wieslander, Paul Straka
  • Publication number: 20180235915
    Abstract: The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.
    Type: Application
    Filed: March 31, 2016
    Publication date: August 23, 2018
    Inventors: Husam MOHAMMED, Anders WIESLANDER, Viktoria HANCOCK, Karin SANDIN, Ola CARLSSON, Torbjorn LINDEN, Anna SZILAGYI
  • Patent number: 9999715
    Abstract: A blood treatment apparatus adapted to preserve a blood treatment unit between blood treatment sessions. The blood treatment apparatus is configured to i) perform a blood treatment session and thereby use the blood treatment unit, ii) fill the blood treatment unit with a preservation fluid comprising at least one treatment fluid concentrate of a type that is used to prepare the treatment fluid, iii) maintain the preservation fluid in the blood treatment unit until a next blood treatment session is prepared, iv) dispatch the preservation fluid from the blood treatment unit in preparation of a next blood treatment session, and v) perform a next blood treatment session and thereby extend the use of the blood treatment unit. A related method is also described.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: June 19, 2018
    Assignee: GAMBRO LUNDIA AB
    Inventors: Thomas Hertz, Mattias Holmer, Lennart Jonsson, Anders Wieslander, Helena Jeppsson
  • Patent number: 9925155
    Abstract: The present invention relates to an acid concentrate dialysis composition comprising a mixture of citric acid and citrate, having pH of less than 3.0, wherein the total concentration of citrate is between 35 mM and 450 mM, and wherein the amount of citric acid is more than 50% of the total concentration of citrate. The acid concentrate dialysis composition is to be combined to form a dialysis solution having a total concentration of citrate of between 1 and 6 mM.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 27, 2018
    Assignee: Gambro Lundia AB
    Inventors: Gunita Forsbäck, Viktoria Hancock, Anders Wieslander, Torbjörn Linden
  • Patent number: 9918999
    Abstract: Method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH from 2.5 to 5.0, and b) terminal sterilization of said at least one compartment and the contents therein, is disclosed, as well as a solution used for preparing the medical solution, a container containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 20, 2018
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Ola Carlsson, Tobjoern Linden, Anders Wieslander
  • Publication number: 20180055989
    Abstract: A control system (23) is arranged to control the operation of an apparatus (200) for extracorporeal blood treatment. The apparatus (200) comprises an extracorporeal blood circuit (20) and a connection system (C) for connecting the blood circuit (20) to the vascular system of a patient. The blood circuit (20) comprises a blood processing device (6), and at least one pumping device (3). The control system is operable to switch between a pre-treatment mode and a blood treatment mode. The blood treatment mode involves operating the blood circuit (20) to pump blood from the vascular system via the connection system (C) through the blood processing device (6) and back to the vascular system via the connection system (C). The control system (23) is operable to obtain measurement data from at least one energy transfer sensor (40) arranged to sense a transfer of energy between the patient and the connection system (C) or between the patient and the blood circuit (20).
    Type: Application
    Filed: October 31, 2017
    Publication date: March 1, 2018
    Inventors: Bo Olde, Kristian Solem, Thomas Hertz, Jan Sternby, Anders Wieslander
  • Publication number: 20180050062
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention the glucose and the at least one magnesium salt, are present as anhydrous components in the dialysis acid precursor composition.
    Type: Application
    Filed: November 1, 2017
    Publication date: February 22, 2018
    Inventors: Ola CARLSSON, Lennart JONSSON, Torbjorn LINDEN, Anders WIESLANDER
  • Patent number: 9833556
    Abstract: A control system (23) is arranged to control the operation of an apparatus (200) for extracorporeal blood treatment. The apparatus (200) comprises an extracorporeal blood circuit (20) and a connection system (C) for connecting the blood circuit (20) to the vascular system of a patient. The blood circuit (20) comprises a blood processing device (6), and at least one pumping device (3). The control system is operable to switch between a pre-treatment mode and a blood treatment mode. The blood treatment mode involves operating the blood circuit (20) to pump blood from the vascular system via the connection system (C) through the blood processing device (6) and back to the vascular system via the connection system (C). The control system (23) is operable to obtain measurement data from at least one energy transfer sensor (40) arranged to sense a transfer of energy between the patient and the connection system (C) or between the patient and the blood circuit (20).
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: December 5, 2017
    Assignee: Gambro Lundia AB
    Inventors: Bo Olde, Kristian Solem, Thomas Hertz, Jan Sternby, Anders Wieslander
  • Patent number: 9821102
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 21, 2017
    Assignee: Gambro Lundia AB
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Publication number: 20170319769
    Abstract: A peritoneal dialysis system includes a disposable set, source(s) of concentrate(s), a water purifier, a sensor, and a control unit. The disposable set includes a water port, an inlet port, a drain port, a water line in fluid communication with the water port, a drain line in fluid communication with the drain port, and a container to hold a dialysis fluid prepared by mixing water and the concentrate(s). The source(s) of concentrate(s) are in fluid communication with the inlet port, and the water purifier is configured to purify water and feed the water towards the water port so the sensor can detect a fluid property. The control unit is configured to deliver dialysis fluid mixed in the disposable set to the drain line and water purified by the water purifier along the water line, into the disposable set, and out the drain line to push dialysis fluid to the sensor.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 9, 2017
    Inventors: Anders Wieslander, Anders Wellings, Olof Jansson
  • Patent number: 9724298
    Abstract: A method to form a dialysis composition includes determining for a patient a prescribed calcium concentration for a dialysis fluid to be administered to the patient. The determination is made based on a non-citrate containing calcium dialysis fluid. 0.5 to 3 mM citrate and 1 to 5 mM total calcium are introduced to the dialysis fluid. The total calcium results in a calcium concentration that is 0.1 to 0.2 mM per 1 mM citrate greater than the prescribed calcium concentration. 0 to 1.5 mM total magnesium is introduced to the dialysis fluid.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 8, 2017
    Assignee: Gambro Lundia AB
    Inventors: Anders Nilsson, Jan Sternby, Anders Wieslander
  • Publication number: 20170157172
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising sodium chloride, at least one dry acid and at least one calcium salt, and optionally potassium salt, magnesium salt, and glucose. In an embodiment, the at least one calcium salt and the optional glucose are present as anhydrous components in the dialysis acid precursor composition.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Patent number: 9655922
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising sodium chloride, at least one dry acid and at least one calcium salt, and optionally potassium salt, magnesium salt, and glucose. In an embodiment, the at least one calcium salt and the optional glucose are present as anhydrous components in the dialysis acid precursor composition.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 23, 2017
    Assignee: Gambro Lundia AB
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Patent number: 9636445
    Abstract: An ambulatory ultrafiltration device includes a blood filter that has a blood side or fluid communication with the vascular system of the subject, an ultrafiltrate side, and a semipermeable membrane disposed between the blood side and the ultrafiltrate side. The ambulatory ultrafiltration also includes a buffer vessel in fluid communication with the blood side of the blood filter, and a blood pump. The blood pump is controlled to alternate between a withdrawal phase and a return phase. In the withdrawal phase, blood is withdrawn on a blood path from the subject via the blood filter to the buffer vessel. In the return phase, blood is returned from the buffer vessel to the subject on the blood path. The blood filter is arranged to remove ultrafiltrate from the blood during at least one of the withdrawal and return phases.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 2, 2017
    Assignee: Gambro Lundia AB
    Inventors: Lennart Jonsson, Jan Sternby, Anders Wieslander
  • Patent number: 9616161
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising sodium chloride, at least one dry acid and at least one calcium salt, and optionally potassium salt, magnesium salt, and glucose. According to the invention said at least one calcium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: April 11, 2017
    Assignee: Gambro Lundia AB
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Publication number: 20160354311
    Abstract: A method to form a dialysis composition includes determining for a patient a prescribed calcium concentration for a dialysis fluid to be administered to the patient. The determination is made based on a non-citrate containing calcium dialysis fluid. 0.5 to 3 mM citrate and 1 to 5 mM total calcium are introduced to the dialysis fluid. The total calcium results in a calcium concentration that is 0.1 to 0.2 mM per 1 mM citrate greater than the prescribed calcium concentration. 0 to 1.5 mM total magnesium is introduced to the dialysis fluid.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 8, 2016
    Inventors: Anders Nilsson, Jan Sternby, Anders Wieslander
  • Patent number: 9452149
    Abstract: Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed for a non-citrate containing dialysis fluid.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: September 27, 2016
    Assignee: Gambro Lundia AB
    Inventors: Anders Nilsson, Jan Sternby, Anders Wieslander